KR102364134B1 - 디아자비시클릭 치환된 이미다조피리미딘 및 호흡 장애의 치료를 위한 그의 용도 - Google Patents
디아자비시클릭 치환된 이미다조피리미딘 및 호흡 장애의 치료를 위한 그의 용도 Download PDFInfo
- Publication number
- KR102364134B1 KR102364134B1 KR1020207000676A KR20207000676A KR102364134B1 KR 102364134 B1 KR102364134 B1 KR 102364134B1 KR 1020207000676 A KR1020207000676 A KR 1020207000676A KR 20207000676 A KR20207000676 A KR 20207000676A KR 102364134 B1 KR102364134 B1 KR 102364134B1
- Authority
- KR
- South Korea
- Prior art keywords
- formula
- group
- compound
- methyl
- mmol
- Prior art date
Links
- 0 C*1C2(C*(C3)I)C3COCC12 Chemical compound C*1C2(C*(C3)I)C3COCC12 0.000 description 15
- ZCDJIDOPTNDVAQ-UHFFFAOYSA-N CC(C)c(cc1)ccc1-c1c(CN(CC2CC3)C3CN2C(OC(C)(C)C)=O)[n](cccn2)c2n1 Chemical compound CC(C)c(cc1)ccc1-c1c(CN(CC2CC3)C3CN2C(OC(C)(C)C)=O)[n](cccn2)c2n1 ZCDJIDOPTNDVAQ-UHFFFAOYSA-N 0.000 description 2
- PALOETWSZLRKLX-UHFFFAOYSA-N CC(C)c(cc1)ccc1-c1c(CN(CC2CC3)CC3N2C(c2c(C3CC3)[o]cn2)=O)[n](cccn2)c2n1 Chemical compound CC(C)c(cc1)ccc1-c1c(CN(CC2CC3)CC3N2C(c2c(C3CC3)[o]cn2)=O)[n](cccn2)c2n1 PALOETWSZLRKLX-UHFFFAOYSA-N 0.000 description 1
- VDKJCAWGDJJKNL-UHFFFAOYSA-N CC(C)c(cc1)ccc1-c1c(CN(CC2CC3)CC3N2C(c2nc(OC)ccc2Cl)=O)[n](cccn2)c2n1 Chemical compound CC(C)c(cc1)ccc1-c1c(CN(CC2CC3)CC3N2C(c2nc(OC)ccc2Cl)=O)[n](cccn2)c2n1 VDKJCAWGDJJKNL-UHFFFAOYSA-N 0.000 description 1
- OGGHXOJOVOYBOH-UHFFFAOYSA-N CC(C)c(cc1)ccc1-c1c(CN(CC2CC3)CC3N2C(c2nc(OC)ccc2F)=O)[n](cccn2)c2n1 Chemical compound CC(C)c(cc1)ccc1-c1c(CN(CC2CC3)CC3N2C(c2nc(OC)ccc2F)=O)[n](cccn2)c2n1 OGGHXOJOVOYBOH-UHFFFAOYSA-N 0.000 description 1
- IQJPMLROUYSIIJ-UHFFFAOYSA-N CC(C)c(cc1)ccc1-c1c(CN(CC2COC3)CC3N2C(c2nc(OC(F)F)ccc2)=O)[n](cccn2)c2n1 Chemical compound CC(C)c(cc1)ccc1-c1c(CN(CC2COC3)CC3N2C(c2nc(OC(F)F)ccc2)=O)[n](cccn2)c2n1 IQJPMLROUYSIIJ-UHFFFAOYSA-N 0.000 description 1
- BRQUOSSZQFFDTO-UHFFFAOYSA-N CC(c1c(-c(cc2)ccc2Cl)nc2nccc[n]12)N(CC1CC2)CC2N1C(OC(C)(C)C)=O Chemical compound CC(c1c(-c(cc2)ccc2Cl)nc2nccc[n]12)N(CC1CC2)CC2N1C(OC(C)(C)C)=O BRQUOSSZQFFDTO-UHFFFAOYSA-N 0.000 description 1
- DCIMLHHFMXLZES-UHFFFAOYSA-N CN(C(CC1)C2)C1CN2I Chemical compound CN(C(CC1)C2)C1CN2I DCIMLHHFMXLZES-UHFFFAOYSA-N 0.000 description 1
- GXIMUJOQZCMEFY-UHFFFAOYSA-N CN1C(CC2)CNC2C1 Chemical compound CN1C(CC2)CNC2C1 GXIMUJOQZCMEFY-UHFFFAOYSA-N 0.000 description 1
- IDQHHCOWPCFYIN-UHFFFAOYSA-N COc(nc1C(N2C3COCC2CN(Cc2c(-c(cc4)ccc4Cl)nc4nccc[n]24)C3)=O)ccc1F Chemical compound COc(nc1C(N2C3COCC2CN(Cc2c(-c(cc4)ccc4Cl)nc4nccc[n]24)C3)=O)ccc1F IDQHHCOWPCFYIN-UHFFFAOYSA-N 0.000 description 1
- PNRHBIXNPFBEKL-UHFFFAOYSA-N COc1nc(C(N2C3COCC2CN(Cc2c(-c(cc4)ccc4Cl)nc4nccc[n]24)C3)=O)ccc1 Chemical compound COc1nc(C(N2C3COCC2CN(Cc2c(-c(cc4)ccc4Cl)nc4nccc[n]24)C3)=O)ccc1 PNRHBIXNPFBEKL-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17176046.5 | 2017-06-14 | ||
| EP17176046 | 2017-06-14 | ||
| EP17193252.8 | 2017-09-26 | ||
| EP17193252 | 2017-09-26 | ||
| PCT/EP2018/064977 WO2018228907A1 (de) | 2017-06-14 | 2018-06-07 | Diazabicyclisch substituierte imidazopyrimidine und ihre verwendung zur behandlung von atemstörungen |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20200014915A KR20200014915A (ko) | 2020-02-11 |
| KR102364134B1 true KR102364134B1 (ko) | 2022-02-18 |
Family
ID=62492660
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020207000676A KR102364134B1 (ko) | 2017-06-14 | 2018-06-07 | 디아자비시클릭 치환된 이미다조피리미딘 및 호흡 장애의 치료를 위한 그의 용도 |
Country Status (29)
| Country | Link |
|---|---|
| US (2) | US11098063B2 (uk) |
| EP (1) | EP3638675B1 (uk) |
| JP (2) | JP6896113B2 (uk) |
| KR (1) | KR102364134B1 (uk) |
| CN (4) | CN115554299A (uk) |
| AR (1) | AR112099A1 (uk) |
| AU (1) | AU2018283331B2 (uk) |
| BR (1) | BR112019026450A2 (uk) |
| CA (1) | CA3066942A1 (uk) |
| CL (1) | CL2019003650A1 (uk) |
| CO (1) | CO2019014047A2 (uk) |
| CR (1) | CR20190563A (uk) |
| CU (1) | CU24603B1 (uk) |
| DO (1) | DOP2019000308A (uk) |
| EA (1) | EA202090043A1 (uk) |
| EC (1) | ECSP19088492A (uk) |
| GE (1) | GEP20227366B (uk) |
| IL (1) | IL271117B (uk) |
| JO (1) | JOP20190284A1 (uk) |
| MA (1) | MA49368A (uk) |
| MX (2) | MX2019014983A (uk) |
| NI (1) | NI201900126A (uk) |
| PE (1) | PE20200016A1 (uk) |
| PH (1) | PH12019502828A1 (uk) |
| SG (1) | SG11201911508XA (uk) |
| TW (1) | TWI801388B (uk) |
| UA (1) | UA125186C2 (uk) |
| UY (1) | UY37773A (uk) |
| WO (1) | WO2018228907A1 (uk) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112018011783A2 (pt) | 2015-12-10 | 2018-12-04 | Bayer Pharma Aktiengesellschaft | derivados de 2-fenil-3-(piperazinometil)imidazo[1,2-a]piridina, como bloqueadores dos canais de task-1 e task-2 para o tratamento de transtornos respiratórios relacionados ao sono |
| JOP20190284A1 (ar) * | 2017-06-14 | 2019-12-11 | Bayer Pharma AG | مركبات إيميدازوبيريميدين مستبدلة بديازا ثنائي الحلقة واستخدامها للمعالجة من اضطرابات التنفس |
| WO2018227427A1 (en) | 2017-06-14 | 2018-12-20 | Bayer Aktiengesellschaft | Substituted bridged diazepane derivatives and use thereof |
| CA3139298A1 (en) | 2019-05-09 | 2020-11-12 | Bayer Aktiengesellschaft | Combination of an a2-adrenoceptor subtype c (alpha-2c) antagonists with a task1/3 channel blocker for the treatment of sleep apnea |
| US20220218700A1 (en) * | 2019-05-09 | 2022-07-14 | Bayer Aktiengesellschaft | Combination of an ?2-adrenoceptor subtype c (alpha-2c) antagonists with a task1/3 channel blocker for the treatment of sleep apnea |
| PE20221025A1 (es) | 2019-11-06 | 2022-06-16 | Bayer Ag | Inhibidores de los receptores a2c adrenergicos |
| IL299652A (en) | 2020-07-06 | 2023-03-01 | Bayer Ag | Combination of an alpha 2-adrenoceptor subtype C antagonist (ALPHA-2C) with a TASK1/3 channel blocker for the treatment of sleep apnea |
| GB202101734D0 (en) * | 2021-02-08 | 2021-03-24 | Cerevance Inc | Novel Compounds |
| TW202342052A (zh) | 2021-12-22 | 2023-11-01 | 德商拜耳廠股份有限公司 | 用於治療睡眠呼吸中止之ｔａｓｋ１／３通道阻斷劑與正腎上腺素再吸收抑制劑之組合 |
| WO2023118102A1 (en) | 2021-12-22 | 2023-06-29 | Bayer Aktiengesellschaft | Combination of a task1/3 channel blocker with a muscarinic receptor antagonist for the treatment of sleep apnea |
| TW202342045A (zh) | 2021-12-22 | 2023-11-01 | 德商拜耳廠股份有限公司 | 用於治療睡眠呼吸中止之ｔａｓｋ１／３通道阻斷劑與ｐ２ｘ３受體拮抗劑之組合 |
| WO2023131638A1 (en) | 2022-01-07 | 2023-07-13 | Bayer Aktiengesellschaft | 2,3-dihydrobenzo [b][1, 4]dioxin-2-ylmethyl)piperazin-1-yl derivates for the treatment of sleep apnea |
| WO2023131640A1 (en) | 2022-01-07 | 2023-07-13 | Bayer Aktiengesellschaft | α2-ADRENOCEPTOR SUBTYPE C ANTAGONISTS FOR THE TREATMENT OF SLEEP APNEA |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013037914A1 (en) | 2011-09-16 | 2013-03-21 | Sanofi | Substituted 4,5,6,7-tetrahydro-1h-pyrazolo[4,3-c]pyridines, their use as medicament, and pharmaceutical preparations comprising them |
| WO2014187922A1 (en) | 2013-05-24 | 2014-11-27 | Iomet Pharma Ltd. | Slc2a transporter inhibitors |
| WO2016084783A1 (ja) | 2014-11-26 | 2016-06-02 | 株式会社村田製作所 | 電子部品の製造方法、電子部品および電子装置 |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19834044A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Neue substituierte Pyrazolderivate |
| DE19834047A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Substituierte Pyrazolderivate |
| DE19943635A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| DE19943639A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Dicarbonsäurederivate mit neuartigen pharmazeutischen Eigenschaften |
| DE19943636A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| DE19943634A1 (de) | 1999-09-13 | 2001-04-12 | Bayer Ag | Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| MY125533A (en) * | 1999-12-06 | 2006-08-30 | Bristol Myers Squibb Co | Heterocyclic dihydropyrimidine compounds |
| US6552037B2 (en) | 2000-06-30 | 2003-04-22 | Neurogen Corporation | 2-Substituted imidazo[1,2-A]pyridine derivatives |
| GB0017256D0 (en) | 2000-07-13 | 2000-08-30 | Merck Sharp & Dohme | Therapeutic agents |
| AR031176A1 (es) | 2000-11-22 | 2003-09-10 | Bayer Ag | Nuevos derivados de pirazolpiridina sustituidos con piridina |
| SE0100568D0 (sv) | 2001-02-20 | 2001-02-20 | Astrazeneca Ab | Compounds |
| DE10110750A1 (de) | 2001-03-07 | 2002-09-12 | Bayer Ag | Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| DE10110749A1 (de) | 2001-03-07 | 2002-09-12 | Bayer Ag | Substituierte Aminodicarbonsäurederivate |
| DE10220570A1 (de) | 2002-05-08 | 2003-11-20 | Bayer Ag | Carbamat-substituierte Pyrazolopyridine |
| DE10247269A1 (de) | 2002-10-10 | 2004-04-22 | Grünenthal GmbH | Substituierte C-Imidazo[1,2-a]pyridin-3-yl-methylamine |
| US7855194B2 (en) * | 2006-03-27 | 2010-12-21 | Hoffmann-La Roche Inc. | Pyrimidine, quinazoline, pteridine and triazine derivatives |
| WO2007124849A2 (en) * | 2006-04-27 | 2007-11-08 | Sanofi-Aventis Deutschland Gmbh | Inhibitors of the task-1 and task-3 ion channel |
| AU2007272854B2 (en) * | 2006-07-14 | 2013-08-01 | Merck Sharp & Dohme Corp. | Bridged diazepan orexin receptor antagonists |
| EP1974729A1 (en) | 2007-03-28 | 2008-10-01 | Santhera Pharmaceuticals (Schweiz) AG | Substituted imidazopyridine derivates as melanocortin- 4 receptor antagonists |
| CA2724842A1 (en) | 2008-05-19 | 2009-11-26 | Sunovion Pharmaceuticals Inc. | Imidazo[1,2-a]pyridine compounds |
| WO2011115804A1 (en) | 2010-03-17 | 2011-09-22 | Ironwood Pharmaceuticals, Inc. | Sgc stimulators |
| MX345762B (es) | 2010-03-18 | 2017-02-15 | Pasteur Institut Korea | Compuestos antiinfecciosos. |
| DE102010021637A1 (de) | 2010-05-26 | 2011-12-01 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung |
| KR20130132393A (ko) | 2010-07-09 | 2013-12-04 | 바이엘 인텔렉쳐 프로퍼티 게엠베하 | 고리-융합된 피리미딘 및 트리아진, 및 심혈관 질환의 치료 및/또는 예방을 위한 그의 용도 |
| DE102010040233A1 (de) | 2010-09-03 | 2012-03-08 | Bayer Schering Pharma Aktiengesellschaft | Bicyclische Aza-Heterocyclen und ihre Verwendung |
| DE102010043379A1 (de) | 2010-11-04 | 2012-05-10 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 6-Fluor-1H-Pyrazolo[4,3-b]pyridine und ihre Verwendung |
| KR20140048079A (ko) | 2011-02-01 | 2014-04-23 | 교와 핫꼬 기린 가부시키가이샤 | 축환 복소환 유도체 |
| WO2012130322A1 (en) | 2011-03-31 | 2012-10-04 | Elara Pharmaceuticals Gmbh | Imidazo [1,2-a]pyridine compounds for use in therapy |
| WO2012143796A2 (en) | 2011-04-21 | 2012-10-26 | Institut Pasteur Korea | Anti-inflammation compounds |
| MX2014002968A (es) | 2011-09-12 | 2014-07-09 | Sanofi Sa | 4,5,6,7 - tetrahidro - 1h - pirazolo [4,3 -c] piridinas sustituidas con indanilo, su uso como medicamento, y preparaciones farmaceuticas que las comprenden. |
| JP5957525B2 (ja) | 2011-09-16 | 2016-07-27 | サノフイ | 置換された、４，５，６，７−テトラヒドロ−１Ｈ−ピラゾロ［４，３−ｃ］ピリジン、医薬としてのそれらの使用、及びそれらを含む医薬製剤 |
| DK2809669T3 (da) | 2012-02-03 | 2017-05-01 | Sanofi Sa | Kondenserede pyrroldicarboxamider og deres anvendelse som farmaceutika |
| PE20161134A1 (es) | 2014-03-26 | 2016-10-29 | Hoffmann La Roche | Compuestos biciclicos como inhibidores de la produccion de autotaxina (atx) y acido lisofosfatidico (lpa) |
| JP2018012645A (ja) | 2014-11-26 | 2018-01-25 | 持田製薬株式会社 | 新規ジアザビシクロ誘導体 |
| US9994570B2 (en) * | 2014-11-26 | 2018-06-12 | Merck Sharp & Dohme Corp. | Bridged diazepane orexin receptor antagonists |
| WO2016085784A1 (en) | 2014-11-26 | 2016-06-02 | Merck Sharp & Dohme Corp. | Methyl diazepane orexin receptor antagonists |
| JP2018016544A (ja) | 2014-12-03 | 2018-02-01 | 持田製薬株式会社 | 新規ジアザビシクロ［２．２．２］オクタン誘導体 |
| JP6846414B2 (ja) | 2015-09-24 | 2021-03-24 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | Ａｔｘ阻害剤としての二環式化合物 |
| BR112018011783A2 (pt) * | 2015-12-10 | 2018-12-04 | Bayer Pharma Aktiengesellschaft | derivados de 2-fenil-3-(piperazinometil)imidazo[1,2-a]piridina, como bloqueadores dos canais de task-1 e task-2 para o tratamento de transtornos respiratórios relacionados ao sono |
| JP2018538296A (ja) * | 2015-12-10 | 2018-12-27 | バイエル・ファルマ・アクティエンゲゼルシャフト | 置換ペルヒドロピロロ［３，４−ｃ］ピロール誘導体およびその使用 |
| JOP20190005A1 (ar) | 2016-07-20 | 2019-01-20 | Bayer Ag | مركبات ديازاهيترو ثنائية الحلقة مستبدلة واستخداماتها |
| JOP20190141A1 (ar) | 2016-12-21 | 2019-06-12 | Bayer Pharma AG | أشكال جرعات صيدلية تحتوي على مثبطات لقناة task-1 و task-3 واستخدامها في معالجة اضطراب تنفسي |
| JOP20190148A1 (ar) | 2016-12-21 | 2019-06-18 | Bayer Pharma AG | أشكال جرعات صيدلية تحتوي على مثبطات قنوات task-1 و task-3 واستخدامها لمعالجة الاضطرابات التنفسية |
| JOP20190284A1 (ar) * | 2017-06-14 | 2019-12-11 | Bayer Pharma AG | مركبات إيميدازوبيريميدين مستبدلة بديازا ثنائي الحلقة واستخدامها للمعالجة من اضطرابات التنفس |
| WO2018227427A1 (en) | 2017-06-14 | 2018-12-20 | Bayer Aktiengesellschaft | Substituted bridged diazepane derivatives and use thereof |
| CA3139298A1 (en) | 2019-05-09 | 2020-11-12 | Bayer Aktiengesellschaft | Combination of an a2-adrenoceptor subtype c (alpha-2c) antagonists with a task1/3 channel blocker for the treatment of sleep apnea |
| US20220218700A1 (en) | 2019-05-09 | 2022-07-14 | Bayer Aktiengesellschaft | Combination of an ?2-adrenoceptor subtype c (alpha-2c) antagonists with a task1/3 channel blocker for the treatment of sleep apnea |
-
2017
- 2017-06-16 JO JOP/2019/0284A patent/JOP20190284A1/ar unknown
-
2018
- 2018-06-07 US US16/622,233 patent/US11098063B2/en active Active
- 2018-06-07 CA CA3066942A patent/CA3066942A1/en active Pending
- 2018-06-07 SG SG11201911508XA patent/SG11201911508XA/en unknown
- 2018-06-07 GE GEAP201815256A patent/GEP20227366B/en unknown
- 2018-06-07 BR BR112019026450-7A patent/BR112019026450A2/pt unknown
- 2018-06-07 EP EP18728646.3A patent/EP3638675B1/de active Active
- 2018-06-07 AU AU2018283331A patent/AU2018283331B2/en active Active
- 2018-06-07 JP JP2019569416A patent/JP6896113B2/ja active Active
- 2018-06-07 CN CN202211199746.0A patent/CN115554299A/zh active Pending
- 2018-06-07 CN CN201880039548.3A patent/CN110719911B/zh active Active
- 2018-06-07 MA MA049368A patent/MA49368A/fr unknown
- 2018-06-07 WO PCT/EP2018/064977 patent/WO2018228907A1/de unknown
- 2018-06-07 KR KR1020207000676A patent/KR102364134B1/ko active IP Right Grant
- 2018-06-07 CN CN202211200547.7A patent/CN115554300A/zh active Pending
- 2018-06-07 CN CN202211200627.2A patent/CN115583959B/zh active Active
- 2018-06-07 CU CU2019000101A patent/CU24603B1/es unknown
- 2018-06-07 EA EA202090043A patent/EA202090043A1/ru unknown
- 2018-06-07 CR CR20190563A patent/CR20190563A/es unknown
- 2018-06-07 PE PE2019002541A patent/PE20200016A1/es unknown
- 2018-06-07 MX MX2019014983A patent/MX2019014983A/es unknown
- 2018-06-07 UA UAA202000222A patent/UA125186C2/uk unknown
- 2018-06-12 TW TW107120117A patent/TWI801388B/zh active
- 2018-06-13 AR ARP180101619A patent/AR112099A1/es unknown
- 2018-06-14 UY UY0001037773A patent/UY37773A/es unknown
-
2019
- 2019-12-02 IL IL271117A patent/IL271117B/en unknown
- 2019-12-11 MX MX2022012716A patent/MX2022012716A/es unknown
- 2019-12-12 CO CONC2019/0014047A patent/CO2019014047A2/es unknown
- 2019-12-12 CL CL2019003650A patent/CL2019003650A1/es unknown
- 2019-12-12 NI NI201900126A patent/NI201900126A/es unknown
- 2019-12-12 EC ECSENADI201988492A patent/ECSP19088492A/es unknown
- 2019-12-13 DO DO2019000308A patent/DOP2019000308A/es unknown
- 2019-12-13 PH PH12019502828A patent/PH12019502828A1/en unknown
-
2021
- 2021-06-04 JP JP2021094338A patent/JP2021127346A/ja active Pending
- 2021-07-16 US US17/305,927 patent/US20220017540A1/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013037914A1 (en) | 2011-09-16 | 2013-03-21 | Sanofi | Substituted 4,5,6,7-tetrahydro-1h-pyrazolo[4,3-c]pyridines, their use as medicament, and pharmaceutical preparations comprising them |
| WO2014187922A1 (en) | 2013-05-24 | 2014-11-27 | Iomet Pharma Ltd. | Slc2a transporter inhibitors |
| WO2016084783A1 (ja) | 2014-11-26 | 2016-06-02 | 株式会社村田製作所 | 電子部品の製造方法、電子部品および電子装置 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102364134B1 (ko) | 디아자비시클릭 치환된 이미다조피리미딘 및 호흡 장애의 치료를 위한 그의 용도 | |
| KR102444687B1 (ko) | 치환된 디아자헤테로비시클릭 화합물 및 그의 용도 | |
| US10414765B2 (en) | Substituted perhydropyrrolo[3,4-c]pyrrole derivatives and the use of same | |
| US11208422B2 (en) | Substituted bridged diazepane derivatives and use thereof as TASK-1 and TASK-3 inhibitors | |
| TW201734012A (zh) | 經取代２－苯基－３－（哌甲基）咪唑并吡啶類及其用途 | |
| EA040559B1 (ru) | Диазабициклические замещенные имидазопиримидины и их применение |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| E902 | Notification of reason for refusal | ||
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant |